EcoDrugPlus


Trade Names	ALPHAREDISOL CYANOKIT HYDROXOCOBALAMIN HYDROXOMIN
Synonyms	Alpharedisol Cobalin-h Cyanokit Hepavit Hydroxocobalamin Hydroxocobalamin acetate Hydroxocobalamin anhydrous Hydroxocobalaminum anhydrous Hydroxocobemine Hydroxomin Hydroxycobalamin Megamilbedoce Neo-cytamen
Status
Molecule Category	UNKNOWN
ATC	B03BA03 V03AB33
UNII	Q40X8H422O

Trade Names

ALPHAREDISOL

CYANOKIT

HYDROXOCOBALAMIN

HYDROXOMIN

Synonyms

Alpharedisol

Cobalin-h

Cyanokit

Hepavit

Hydroxocobalamin

Hydroxocobalamin acetate

Hydroxocobalamin anhydrous

Hydroxocobalaminum anhydrous

Hydroxocobemine

Hydroxomin

Hydroxycobalamin

Megamilbedoce

Neo-cytamen

Status

Molecule Category

UNKNOWN

ATC

B03BA03 V03AB33

UNII

Q40X8H422O


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Property Name	Value
Molecular Formula	C62H89CoN13O15P
Molecular Weight	1346.38
AlogP	None
Hydrogen Bond Acceptor	None
Hydrogen Bond Donor	None
Number of Rotational Bond	None
Polar Surface Area	None
Molecular species	None
Aromatic Rings	None
Heavy Atoms	None

Property Name

Value

Molecular Formula

C62H89CoN13O15P

Molecular Weight

1346.38

AlogP

None

Hydrogen Bond Acceptor

None

Hydrogen Bond Donor

None

Number of Rotational Bond

None

Polar Surface Area

None

Molecular species

None

Aromatic Rings

None

Heavy Atoms

None

Resources	Reference
ChEMBL	CHEMBL2103737
FDA SRS	Q40X8H422O
PubChem	44475014

Resources

Reference

ChEMBL

CHEMBL2103737

FDA SRS

Q40X8H422O

PubChem

44475014


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

HYDROXOCOBALAMIN

Physicochemical Descriptors

Cross References